Last reviewed · How we verify

NCT04802044: CARAMEL

COVID-19, Aging, and Cardiometabolic Risk Factors Study

Status unknown Last updated 18 April 2022
What this trial tests

trial in Covid19 in 440 participants. Status unknown.

Timeline
8 December 2020
Primary endpoint
31 December 2022
31 December 2023

Quick facts

Lead sponsorIndonesia University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment440
Start date8 December 2020
Primary completion31 December 2022
Estimated completion31 December 2023
Sites2 locations across Indonesia

Conditions studied

Sponsor

Indonesia University

Who can join

18 and older, any sex, with Covid19 or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID-19 pandemic has made a tremendous impact on Indonesian economic and health care system especially with the double burden of diseases facing by Indonesia as a developing country. The prevalence of non-communicable diseases such as obesity, type diabetes, and cardiovascular diseases is increasing. These diseases along with older age have been known as an established risk factors for higher mortality and severe clinical disease entity in COVID-19 infection. Although, there is still some part of patients with these co-morbidities that only present with mild symptoms when infected with SARS-CoV-2, even for some without any symptoms. Thus, it would be very interesting to evaluate how are these role of aging and cardiometabolic parameters in the clinical disease course of COVID-19 infection, and how are the relationship with the immune system.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Altered Body Composition and Cytokine Production in Patients with Elevated HOMA-IR after SARS-CoV-2 Infection: A 12-Month Longitudinal Study.
    Kartika R, Subekti I, Kurniawan F, Wafa S, et al · · 2024 · cited 3× · PMID 39062154 · DOI 10.3390/biomedicines12071581
  2. Reduced IFN-γ-expressing SARS-CoV-2 specific CD4<sup>+</sup> T cells and transient CD8 <sup>+</sup> T cell activation associate with higher HOMA-IR 1-year post COVID-19 in obese individuals.
    Kartika R, Tahapary DL, Kurniawan F, Wafa S, et al · · 2025 · PMID 40830616 · DOI 10.1038/s41598-025-11714-3

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Indonesia University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04802044.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing